Early Results: Antiplatelet Drug Cangrelor Appears Effective For PCI

The experimental antiplatelet drug cangrelor was superior to traditional clopidogrel in reducing ischemic events at 48 hours in PCI patients, according to the Medicines Company, which is developing the drug. The company today announced positive results from the phase 3 CHAMPION PHOENIX trial, a randomized, double-blind study comparing intravenous cangrelor to oral clopidogrel in PCI patients. The primary endpoint was the composite of death, MI, revascularization and stent thrombosis at 48 hours. Click here to read the full story on Forbes.  

Source: CardioBrief - January 8, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Antiplatelet drug Cangrelor clopidogrel Conventional PCI Medicines Company Stent Source Type: blogs